Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY:DGX)

179.33 -0.30 (-0.17%)
Official Closing Price Updated: 7:00 PM EDT, Jul 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Quest’s (NYSE:DGX) Q4: Beats On Revenue
Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 14.6% year on year to $2.62 billion. Its non-GAAP profit... 
Via StockStory
What 6 Analyst Ratings Have To Say About Quest Diagnostics
Via Benzinga
Why Quest Diagnostics Stock Was Blasting Higher Today
Via The Motley Fool
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.
Discover the S&P500 stocks that are experiencing unusual trading volume in today's session. Find out more about these stocks below. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Analyst Expectations For Quest Diagnostics's Future
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
The Analyst Landscape: 8 Takes On Quest Diagnostics
Via Benzinga
Quest Diagnostics Stock Hits Over 2-Month High On Q4 Beat, Dividend Hike: Retail Cheer Grows
Quest completed eight acquisitions in 2024, including LifeLabs, expanded its advanced diagnostics portfolio, and extended its market reach with new clinical, consumer, and health plan customers. 
Via Stocktwits
Quest Diagnostics Delivers Q4 Earnings Beat: The Details
Quest Diagnostics reported fourth-quarter revenue of $2.62 billion, beating analyst estimates of $2.58 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of $2.23... 
Via Benzinga
Quest Diagnostics EPS Tops Predictions
Quest Diagnostics saw robust growth in earnings and revenue, surpassing expectations for Q4 2024. 
Via The Motley Fool
IBM Posts Upbeat Earnings, Joins Oshkosh, Las Vegas Sands, Nokia, Quest Diagnostics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
(DGX) - Analyzing Quest Diagnostics's Short Interest
Via Benzinga
How Is The Market Feeling About Quest Diagnostics?
Via Benzinga
What Analysts Are Saying About Quest Diagnostics Stock
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics
Via Benzinga
Earnings Scheduled For January 30, 2025
Via Benzinga
Friday's session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Tesla To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
This Boeing Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.
Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S. 
Via News Direct
Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services
U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending. 
Via Benzinga
Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
Quest to Support Mainz Biomed’s ReconAAsense FDA Study and Has Option to Commercialize Test Kit Assuming FDA Approval 
From Mainz BioMed NV
Via GlobeNewswire
Tesla To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Guardant Health Stock Sees RS Rating Jump To 83
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. 
Via Investor's Business Daily
Navigating Earnings Season: Weather Any Storm
The consequences of hurricanes like Helene and Milton are—typically—quickly shrugged aside by markets as one-off events. That is mostly correct. But not entirely so. For some companies, the revenue and... 
Via Talk Markets
Donald Trump's Second Term Could Reshape US Healthcare System, With Major Impacts on Affordable Care Act And Medicare
Trump's second term could bring significant changes to U.S. healthcare, with cuts to ACA subsidies and potential Medicare privatization. 
Via Benzinga
Topics Government
Laboratory Corp Q3 Earnings Beat Street View, Investors Overlook Hurricane Helene Impact
LabCorp Q3 2024 EPS beats expectations at $3.50, with 7.4% revenue growth to $3.28B. Adjusted EPS guidance revised due to weather. 
Via Benzinga
Topics Earnings
This Snap Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.